^
Association details:
| Biomarker: | PBRM1 mutation + SETD2 mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Torisel (temsirolimus) (mTOR inhibitor) + Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data
Published date:
09/04/2020
Excerpt:
Other metastatic PRCC2 patient with somatic PBRM1 and SETD2 mutations had over 5 years of overall survival with axitinib treatment....The patient without genetic alteration of FH showed a durable response to temsirolimus and axitinib [a tyrosine kinase inhibitor (TKI), which targets vascular endothelial growth factor-receptor 1–3 (VEGFR 1–3)]. We observed PBRM1 and SETD2 mutations in his disease and he had relatively long survival duration.
DOI:
10.21037/atm-20-3466
